Evaxion Biotech A/S (NASDAQ:EVAX) Short Interest Up 709.3% in December

Evaxion Biotech A/S (NASDAQ:EVAX) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totalling 980,100 shares, an increase of 709.3% from the December 15th total of 121,100 shares. Based on an average daily trading volume, of 335,500 shares, the days-to-cover ratio is currently 2.9 days.

Evaxion Biotech A/S Price Performance

NASDAQ:EVAX traded down $3.69 during trading hours on Monday, hitting $0.81. The company’s stock had a trading volume of 192,828 shares, compared to its average volume of 202,235. The business’s 50-day moving average is $6.99 and its two-hundred day moving average is $12.03. The company has a market capitalization of $4.75 million, a PE ratio of -2.79 and a beta of -0.23. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 1.00. Evaxion Biotech A/S has a 52-week low of $0.81 and a 52-week high of $13.61.

Evaxion Biotech A/S (NASDAQ:EVAX) last posted its earnings results on Thursday, October 31st. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.40. The firm had revenue of $3.02 million during the quarter, compared to analyst estimates of $0.19 million. As a group, research analysts anticipate that Evaxion Biotech A/S will post -0.15 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price target on shares of Evaxion Biotech A/S in a report on Friday, November 1st.

Institutional Trading of Evaxion Biotech A/S

A hedge fund recently raised its stake in Evaxion Biotech A/S stock. Armistice Capital LLC boosted its holdings in Evaxion Biotech A/S (NASDAQ:EVAX) by 6.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 392,000 shares of the company’s stock after buying an additional 25,000 shares during the period. Armistice Capital LLC owned 7.24% of Evaxion Biotech A/S worth $1,137,000 at the end of the most recent reporting period. 11.04% of the stock is currently owned by institutional investors.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.